Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
A synthetic copy of the 28-residue neuropeptide VIP, studied in acute lung injury.
Also known as: synthetic VIP · RLF-100 · Zyesami
Part of the Foundational & therapeutic peptides cluster
Overview
Aviptadil is an injectable synthetic form of human vasoactive intestinal peptide (VIP), a 28-amino-acid neuropeptide. It has been investigated for acute respiratory distress syndrome and other lung conditions, and a VIP-phentolamine combination has approval in some markets for erectile dysfunction. This page is educational and is not medical advice.
Source & context
Biological / chemical source: Synthetic form of human vasoactive intestinal peptide
Primary research or clinical context: Synthetic form of human VIP investigated for respiratory conditions such as ARDS; a combination with phentolamine has approval in some markets for erectile dysfunction
What VIP does
Vasoactive intestinal peptide is a signaling neuropeptide with vasodilatory, bronchodilatory, and anti-inflammatory activity. Because VIP receptors are abundant in the lung, synthetic VIP has been of interest in respiratory research.
Investigational status
Aviptadil received attention during COVID-19 research for severe respiratory failure and holds fast-track designation in the US for that context. Investigational uses remain under study rather than broadly approved.
Sequence
One-letter sequence commonly cited for Aviptadil (educational; isoforms and modifications may differ):
HSDAVFTDNYTRLRKQMAVKKYLNSILN
Residues plotted ~100° apart around an α-helix — clustering of one color reveals an amphipathic face.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Aviptadil (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- IUPHAR/BPS source snapshot · 2026-10-01
- PubChem molecular record · 2026-10-01
- Molecular formula
- C147H237N43O43S
- Average reference mass
- ≈ 3,326.8
- Status
- Approved medicine in at least one jurisdiction (IUPHAR record)
- PubChem CID: 16132300
- IUPHAR ligand: 10891
- CAS RN: 40077-57-4
- UNII: A67JUW790C
Chemistry values: PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 9 registered studies with “Aviptadil” as an intervention (snapshot 2026-09-06). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT05137795 | Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 | Phase 3 | withdrawn | 2026-05-14 |
| NCT04488081 | I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients | Phase 2 | active not recruiting | 2026-03-16 |
| NCT04843761 | ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 | Phase 3 | completed | 2025-10-24 |
| NCT06729606 | Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial) | Phase 3 | completed | 2025-10-09 |
| NCT04536350 | Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS | Phase 2 | terminated | 2024-01-18 |
| NCT04311697 | Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure | Phase 3 | completed | 2023-07-24 |
Aviptadil — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Aviptadil (source record; form not independently established)Average reference mass: 3,326.8 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
FAQ about Aviptadil
What is Aviptadil?+
Aviptadil is an injectable synthetic form of human vasoactive intestinal peptide (VIP), a 28-amino-acid neuropeptide. It has been investigated for acute respiratory distress syndrome and other lung conditions, and a VIP-phentolamine combination has approval in some markets for erectile dysfunction. This page is educational and is not medical advice.
What Canadian product status is recorded for Aviptadil?+
Canadian product status for Aviptadil has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Aviptadil?+
Aviptadil is commonly described as approximately 28 amino acids (Vasoactive intestinal peptide (VIP) analog).
Related peptides
References & further reading
- 1.Mukherjee et al. (2022). Anticipated pharmacological role of Aviptadil on COVID-19. Environ Sci Pollut Res Int
- 2.Keijzers (2001). Aviptadil (Senatek). Curr Opin Investig Drugs
- 3.Mahmoudzadeh et al. (2023). Peptiligase, an enzyme for efficient chemo-enzymatic synthesis of aviptadil. Int J Biol Macromol
- 4.Brown et al. (2023). Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respir Med
- 5.Gross et al. (2014). Analytics of the therapeutic peptide aviptadil by sheathless CE-MS and comparison with nanoRP-HPLC-MS. J Pharm Biomed Anal
- 6.Vora et al. (2023). Aviptadil: A promising treatment option for acute respiratory distress syndrome. Indian J Tuberc
- 7.Udupa et al. (2025). Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis. Indian J Crit Care Med
- 8.Esendagli et al. (2025). Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19. Med Princ Pract
- 9.PubChem — compound summary for Aviptadil (CID 16132300)
- 10.Wikipedia — Aviptadil